
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group is a leading provider of regenerative biomaterial products made from human amniotic membrane, birth tissues, and human skin & bone, with a proven track record of helping clinicians treat chronic wounds for over a decade. Despite recent challenges in the wound care market due to reimbursement changes and payment processes, the company has proactively implemented cost reduction initiatives and its CEO has taken a 20% salary reduction, positioning it for strong future growth in the wound care, surgical, and orthopedics markets with its best-in-class suite of clinical data and vertically integrated manufacturing infrastructure.
Bears say
MiMedx Group is facing challenges related to unique and complex reimbursement situations for their key market, leading to a decline in net sales in the first quarter of 2026. The company has implemented a restructuring and cost reduction plan, but this may only provide temporary relief and could have long-term impacts on their sales and margins. Additionally, they face risks related to tissue donorship, regulation of their products, and contracts with GPOs and IDNs, which could adversely impact their revenue and cash flow. However, with an established track record and strong clinical data, as well as opportunities for growth in the Advanced Surgical and international Wound Care segments, MiMedx may be able to weather the storm and see a return to solid, double-digit revenue growth in the long run.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares